Context Therapeutics Inc. (NASDAQ:CNTX) Sees Significant Growth in Short Interest

Context Therapeutics Inc. (NASDAQ:CNTX) was the target of a large growth in short interest during the month of June. As of June 30th, there was short interest totaling 3,211,049 shares, a growth of 275.7% from the June 15th total of 854,672 shares. Currently, 3.7% of the shares of the company are sold short. Based on an average trading volume of 4,938,871 shares, the short-interest ratio is currently 0.7 days.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Octagon Capital Advisors LP acquired a new stake in Context Therapeutics in the 1st quarter worth about $13,755,000. Millennium Management LLC purchased a new stake in Context Therapeutics during the 4th quarter worth approximately $3,824,000. Marshall Wace LLP raised its holdings in shares of Context Therapeutics by 7,153.7% during the fourth quarter. Marshall Wace LLP now owns 2,593,198 shares of the company’s stock valued at $3,812,000 after acquiring an additional 2,557,448 shares during the last quarter. Seven Fleet Capital Management LP acquired a new position in shares of Context Therapeutics during the first quarter valued at approximately $500,000. Finally, Renaissance Technologies LLC raised its holdings in shares of Context Therapeutics by 58.8% during the fourth quarter. Renaissance Technologies LLC now owns 508,329 shares of the company’s stock valued at $747,000 after acquiring an additional 188,202 shares during the last quarter. 14.03% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of research firms have recently weighed in on CNTX. Piper Sandler increased their price objective on shares of Context Therapeutics from $4.00 to $7.00 and gave the stock an “overweight” rating in a research note on Tuesday, March 24th. Wall Street Zen upgraded shares of Context Therapeutics from a “strong sell” rating to a “sell” rating in a research report on Sunday. D. Boral Capital reaffirmed a “buy” rating and issued a $9.00 price target on shares of Context Therapeutics in a report on Tuesday, March 24th. Guggenheim reaffirmed a “buy” rating and set a $5.00 price target on shares of Context Therapeutics in a research report on Tuesday, March 24th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Context Therapeutics in a research report on Monday, April 20th. One investment analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $6.17.

Context Therapeutics Price Performance

NASDAQ CNTX traded up $0.06 on Friday, hitting $0.65. The company had a trading volume of 3,904,766 shares, compared to its average volume of 5,103,142. The company’s fifty day moving average price is $1.60 and its 200-day moving average price is $2.03. The company has a market capitalization of $59.99 million, a PE ratio of -1.55 and a beta of 1.75. Context Therapeutics has a 12-month low of $0.55 and a 12-month high of $3.62.

Context Therapeutics (NASDAQ:CNTX) last posted its quarterly earnings data on Wednesday, May 6th. The company reported ($0.09) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.12) by $0.03. On average, sell-side analysts anticipate that Context Therapeutics will post -0.39 EPS for the current year.

Context Therapeutics Company Profile

Context Therapeutics (NASDAQ: CNTX) is a clinical-stage biopharmaceutical company focused on the discovery and development of precision therapies for genetically defined patient populations in oncology. The company’s research model centers on identifying novel targets and designing small-molecule and biologic candidates that address key drivers of tumor growth and resistance. Context Therapeutics leverages a biomarker-driven approach to maximize the probability of clinical response, tailoring its development programs to specific molecular subgroups within solid tumors.

With a pipeline advancing through early clinical trials, Context Therapeutics emphasizes strategic collaborations and academic partnerships to accelerate the translation of laboratory findings into patient-focused studies.